Immune & Thymic Peptides (Thymosin Alpha-1, LL-37)

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Immune & Thymic Peptides (Thymosin Alpha-1, LL-37) - References

---

1. Pharmacodynamics & Mechanism of Action

Age-related thymic involution (which replaces $>80\%$ of functional thymic epithelial tissue with adipose by age 50) drives immunosenescence—characterized by exhausted ${\text{CD8}}^{+}$ T-cells, depleted naive T-cell repertoires, impaired Natural Killer (NK) surveillance of senescent/pre-malignant cells, and chronic sterile inflammaging ($\text{IL-6, TNF-}\alpha$).

• Thymosin Alpha-1 ($\text{T}\alpha 1$ / Zadaxin; 28-AA N-acetylated peptide): Cleaved endogenously from Prothymosin-$\alpha$ in the thymus gland; approved clinically in $>35$ countries for viral hepatitis, oncology vaccine adjuvancy, and sepsis immunoparalysis.
  • Pleiotropic TLR2/TLR9 Dendritic Cell Priming: Binds Toll-Like Receptors 2, 4, and 9 (TLR2/4/9) on myeloid and plasmacytoid dendritic cells, activating MyD88 $\to$ IRF3/NF-$\kappa$B signaling to stimulate IL-2, IFN-$\alpha$, and IFN-$\gamma$ production while upregulating MHC Class I antigen presentation on virally infected and neoplastic cells.
  • Bidirectional Immune Homeostasis ($\text{Th1}$ vs. $\text{Treg}$): Crucially, $\text{T}\alpha 1$ is an immunomodulator, not a crude immunostimulant: while it drives ${\text{CD4}}^{+}/{\text{CD8}}^{+}$ T-cell maturation and NK cell cytotoxicity during infection, it simultaneously activates Indoleamine 2,3-Dioxygenase 1 (IDO1) in plasmacytoid dendritic cells—generating ${\text{FoxP3}}^{+}$ Regulatory T-cells ($\text{Tregs}$) and IL-10 to quench cytokine storms and autoimmune hyper-reactivity.
• LL-37 (Human Cathelicidin; 37-AA cationic amphipathic $\alpha$-helical peptide): The sole human member of the cathelicidin antimicrobial peptide (AMP) family, cleaved by proteinase 3 from the hCAP18 precursor in neutrophils, macrophages, and barrier epithelia.
  • Electrostatic Toroidal-Pore Disruption & Anti-Biofilm Activity: Carries a net $+6$ cationic charge at physiological pH; binds negatively charged bacterial lipopolysaccharide (LPS), lipoteichoic acid, and fungal/viral envelopes via the “carpet” and “toroidal pore” models—physically lysing multidrug-resistant pathogens (Pseudomonas, Staphylococcus, Borrelia, Candida), dispersing quorum-sensing biofilms, and neutralizing circulating LPS endotoxin before it can trigger TLR4 sepsis cascades.
  • Direct Vitamin D3 Transcriptional Link: The human CAMP gene encoding hCAP18/LL-37 contains a consensus Vitamin D Response Element (VDRE) in its promoter; calcitriol ($1,25(\text{OH}{)}_2{\text{D}}_3$ from Vitamin D3, K2 & Calcium Homeostasis) directly upregulates endogenous LL-37 expression by $+3\text{- to }10\text{-fold}$ in human macrophages and epithelia.
• VIP (Vasoactive Intestinal Peptide; 28-AA neuropeptide): Potent ${\text{VPAC}}_1/{\text{VPAC}}_2$ receptor agonist used intranasally in chronic inflammatory response syndrome (CIRS), pulmonary arterial hypertension, and mast cell activation; downregulates TGF-$\beta 1$, C4a, and MMP-9 while restoring ${\text{CD4}}^{+}{\text{CD25}}^{+}$ $\text{Treg}$ counts.

---

2. Pharmacokinetics & Clinical Profiles

Peptide	Sequence Length & MW	Primary Clinical Target	Half-Life & Dosing Cadence
Thymosin Alpha-1 ($\text{T}\alpha 1$)	28 AA ($3,108\text{ Da}$)	Viral clearance, NK/T-cell immunosenescence reversal, Treg balance, vaccine adjuvant	$t_{1/2}\approx 1.9\text{ h}$ ($T_{\max }\approx 1\text{–}2\text{ h}$); immune shifts persist 3–7 days (twice-weekly dosing)
LL-37	37 AA ($4,493\text{ Da}$)	Recalcitrant biofilms, SIBO/dysbiosis, tick-borne/intracellular pathogens, wound healing	$t_{1/2}\approx 30\text{–}60\text{ min}$; daily SubQ during short 2–4 week eradication blocks
VIP	28 AA ($3,326\text{ Da}$)	Neuroimmune/mast-cell calming, pulmonary vasodilation, TGF-$\beta 1$ reduction	$t_{1/2}\approx 1\text{–}2\text{ min}$ in plasma; requires $2\text{–}4\times /\text{day}$ intranasal micro-sprays

---

3. Dosing, Cycling & Synergies

• Standard Protocol:
  • Thymosin Alpha-1 (Longevity / Immunosenescence Prophylaxis): $1.5\text{–}1.6\text{ mg}$ SubQ twice weekly (e.g., Monday/Thursday) in 6–12 week blocks during winter or high-travel periods.
  • Thymosin Alpha-1 (Acute Viral Onset Rescue): $1.6\text{ mg}$ SubQ once or twice daily for 5 to 7 consecutive days at the earliest prodrome of viral infection.
  • LL-37 (Biofilm / Pathogen Eradication): $100\text{–}125\mu \text{g/day}$ SubQ for 2 to 4 weeks maximum, followed by at least 4–6 weeks off.
• Synergies:
  • Endogenous LL-37 Induction: Vitamin D3, K2 & Calcium Homeostasis ($5,000\text{ IU/day}$ D3) + Sodium Butyrate ($600\text{–}1,200\text{ mg}$) + Phenylbutyrate synergistically activate the CAMP gene promoter to boost endogenous mucosal LL-37 without injection.
  • Thymic Restoration Stack: Thymosin Alpha-1 + Khavinson Bioregulators (Epitalon, Pinealon) (Thymalin / Vilon) + Zinc ($15\text{–}30\text{ mg/day}$, obligate cofactor for the thymic hormone Thymulin).
• Contraindications & Biomarkers to Monitor:
  • Contraindications: Thymosin Alpha-1 is contraindicated in solid organ transplant recipients on immunosuppressive therapy (cyclosporine/tacrolimus, due to graft rejection risk). LL-37 is strictly contraindicated in psoriasis, rosacea, and active systemic lupus erythematosus (SLE): in psoriasis and rosacea, excess LL-37 complexes with self-DNA/RNA to activate plasmacytoid dendritic cell TLR9, driving autoimmune dermal inflammation; high-dose LL-37 also induces MrgprX2-mediated mast cell degranulation and Jarisch-Herxheimer die-off reactions.
  • Biomarkers: CBC with Differential (Absolute Lymphocyte Count & Neutrophil-to-Lymphocyte Ratio [NLR]—target $1.2\text{–}1.8$), Lymphocyte Subset Panel (${\text{CD4}}^{+}/{\text{CD8}}^{+}$ ratio, ${\text{CD56}}^{+}$ NK cells, ${\text{CD45RA}}^{+}$ Naive vs. ${\text{CD45RO}}^{+}$ Memory T-cells), hs-CRP, and TGF-$\beta 1$.

---

4. Key Scientific Evidence Summary

• Sepsis Mortality Reduction (ETASS Trial): Wu et al. (2013) demonstrated in a multicenter randomized controlled trial in Critical Care ($N=361$) that Thymosin Alpha-1 reduced 28-day all-cause mortality in severe sepsis by $-9.0\%$ absolute risk reduction ($26.0\%$ vs. $35.0\%,p=0.049$) while restoring monocyte HLA-DR expression.
• Lymphopenia Reversal & T-Cell Restoration: Liu et al. (2020) and Garaci et al. showed that Thymosin Alpha-1 reverses severe ${\text{CD4}}^{+}$ and ${\text{CD8}}^{+}$ T-cell exhaustion (downregulating PD-1 and TIM-3 exhaustion markers) and promotes thymopoiesis (increasing T-cell receptor excision circles, TRECs).
• Vitamin D–Cathelicidin Innate Immunity: Liu et al. (2006) published in Science that TLR activation of human macrophages upregulates VDR and CYP27B1, driving LL-37 (cathelicidin) synthesis required to kill intracellular Mycobacterium tuberculosis.

See full study breakdowns in Immune & Thymic Peptides (Thymosin Alpha-1, LL-37) - References.